Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity

被引：11

作者：

Wu, Meng-Ju ^{[1
,2
,3
,4
]}

Kondo, Hiroshi ^{[1
,2
,3
,4
]}

Kammula, Ashwin V. ^{[1
,3
,4
]}

Shi, Lei ^{[1
,2
,3
,4
]}

Xiao, Yi ^{[5
]}

Dhiab, Sofiene ^{[1
,2
,3
,4
]}

Xu, Qin ^{[1
,2
,3
,4
]}

Slater, Chloe J. ^{[1
,2
,3
,6
,7
]}

Avila, Omar I. ^{[1
,3
,4
]}

Merritt, Joshua ^{[1
,2
,3
,4
]}

Kato, Hiroyuki ^{[1
,2
,3
,4
]}

Kattel, Prabhat ^{[1
,2
,3
,4
]}

Sussman, Jonathan ^{[8
,9
,10
]}

Gritti, Ilaria ^{[1
,2
,3
,4
]}

Eccleston, Jason ^{[8
,9
]}

Sun, Yi ^{[1
]}

Cho, Hyo Min ^{[1
,2
,3
,4
]}

Olander, Kira ^{[4
]}

Katsuda, Takeshi ^{[8
,9
]}

Shi, Diana D. ^{[5
,11
]}

Savani, Milan R. ^{[5
,12
]}

Smith, Bailey C. ^{[5
]}

Cleary, James M. ^{[13
]}

Mostoslavsky, Raul ^{[1
,2
,3
,4
]}

Vijay, Vindhya ^{[1
,2
,3
,4
]}

Kitagawa, Yosuke ^{[14
]}

Wakimoto, Hiroaki ^{[14
]}

Jenkins, Russell W. ^{[1
,3
,4
,15
]}

Yates, Kathleen B. ^{[1
,3
,4
]}

Paik, Jihye ^{[16
]}

Tassinari, Ania ^{[7
]}

Saatcioglu, Duygu Hatice ^{[7
]}

Tron, Adriana E. ^{[7
]}

Haas, Wilhelm ^{[1
,3
,4
]}

Cahill, Daniel ^{[14
]}

Mcbrayer, Samuel K. ^{[5
,17
]}

Manguso, Robert T. ^{[1
,3
,4
]}

Bardeesy, Nabeel ^{[1
,2
,3
,4
]}

机构：

[1] Massachusetts Gen Hosp, Krantz Family Ctr Canc Res, Boston, MA 02114 USA

[2] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA

[3] Harvard Med Sch, Dept Med, Boston, MA 02115 USA

[4] Massachusetts Inst Technol & Harvard, Broad Inst, Cambridge, MA 02139 USA

[5] Univ Texas Southwestern Med Ctr Dallas, Childrens Med Ctr Res Inst, Dallas, TX USA

[6] Univ Paris Saclay, Inst Gustave Roussy, INSERM, U1015, Villejuif, France

[7] Servier Pharmaceut LLC, Boston, MA USA

[8] Univ Penn, Perelman Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA USA

[9] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA

[10] Univ Penn, Perelman Sch Med, Grad Grp Genom & Computat Biol, Philadelphia, PA USA

[11] Harvard Med Sch, Dept Radiat Oncol, Dana Farber Brigham & Womens Canc Ctr, Boston, MA 02115 USA

[12] Univ Texas Southwestern Med Ctr, Med Scientist Training Program, Dallas, TX USA

[13] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Div Gastrointestinal Oncol, Boston, MA USA

[14] Harvard Med Sch, Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA USA

[15] Harvard Med Sch, Harvard Program Therapeut Sci, Lab Syst Pharmacol, Boston, MA USA

[16] Cornell Univ, Weill Med Coll, Sandra & Edward Meyer Canc Ctr, Dept Pathol & Lab Med, New York, NY USA

[17] Univ Texas SouthWestern Med Ctr Dallas, Dept Pediat, Dallas, TX USA

来源：

SCIENCE | 2024年 / 385卷 / 6705期

基金：

美国国家卫生研究院; 日本学术振兴会;

关键词：

DIFFERENTIAL EXPRESSION ANALYSIS; REVERSE-TRANSCRIPTASE; ENDOGENOUS RETROVIRUSES; TRANSPOSABLE ELEMENTS; CELL-LINE; MUTATIONS; CANCER; (R)-2-HYDROXYGLUTARATE; IDENTIFICATION; MAINTENANCE;

D O I：

10.1126/science.adl6173

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Isocitrate dehydrogenase 1 (IDH1) is the most commonly mutated metabolic gene across human cancers. Mutant IDH1 (mIDH1) generates the oncometabolite (R)-2-hydroxyglutarate, disrupting enzymes involved in epigenetics and other processes. A hallmark of IDH1-mutant solid tumors is T cell exclusion, whereas mIDH1 inhibition in preclinical models restores antitumor immunity. Here, we define a cell-autonomous mechanism of mIDH1-driven immune evasion. IDH1-mutant solid tumors show selective hypermethylation and silencing of the cytoplasmic double-stranded DNA (dsDNA) sensor CGAS, compromising innate immune signaling. mIDH1 inhibition restores DNA demethylation, derepressing CGAS and transposable element (TE) subclasses. dsDNA produced by TE-reverse transcriptase (TE-RT) activates cGAS, triggering viral mimicry and stimulating antitumor immunity. In summary, we demonstrate that mIDH1 epigenetically suppresses innate immunity and link endogenous RT activity to the mechanism of action of a US Food and Drug Administration-approved oncology drug.

引用

页数：20

共 50 条

[21] Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo
Pusch, Stefan
Krausert, Sonja
Fischer, Viktoria
Balss, Joerg
Ott, Martina
Schrimpf, Daniel
Capper, David
Sahm, Felix
Eisel, Jessica
Beck, Ann-Christin
Jugold, Manfred
Eichwald, Viktoria
Kaulfuss, Stefan
Panknin, Olaf
Rehwinkel, Hartmut
Zimmermann, Katja
Hillig, Roman C.
Guenther, Judith
Toschi, Luisella
Neuhaus, Roland
Haegebart, Andrea
Hess-Stumpp, Holger
Bauser, Markus
Wick, Wolfgang
Unterberg, Andreas
Herold-Mende, Christel
Platten, Michael
von Deimling, Andreas
ACTA NEUROPATHOLOGICA, 2017, 133 (04) : 629 - 644
[22] Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Gupta, Charu
Kaulfuss, Stefan
Goerlich, Kerstin
Othman, Basem
Chaturvedi, Anuhar
Heuser, Michael
ANNALS OF HEMATOLOGY, 2020, 99 (06) : 1415 - 1417
[23] PLK1 INHIBITION ENHANCES TEMOZOLOMIDE EFFICACY IN IDH1 MUTANT GLIOMAS
Bahassi, El Mustapha
Koncar, Robert
Chu, Zhengtao
Qi, Chiaoyang
Romick-Rosendale, Lindsey
Wells, Susanne
Chan, Timothy
NEURO-ONCOLOGY, 2016, 18 : 68 - 68
[24] Inhibition of Glutaminase Preferentially Slows Growth of Glioma Cells with Mutant IDH1
Seltzer, Meghan J.
Bennett, Bryson D.
Joshi, Avadhut D.
Gao, Ping
Thomas, Ajit G.
Ferraris, Dana V.
Tsukamoto, Takashi
Rojas, Camilo J.
Slusher, Barbara S.
Rabinowitz, Joshua D.
Dang, Chi V.
Riggins, Gregory J.
CANCER RESEARCH, 2010, 70 (22) : 8981 - 8987
[25] Cassane diterpenoid derivative induces apoptosis in IDH1 mutant glioma cells through the inhibition of glutaminase in vitro and in vivo
Huang, Guo-dong
Chen, Fan-fan
Ma, Guo-Xu
Li, Wei-ping
Zheng, Yue-yang
Meng, Xiang-bao
Li, Zong-yang
Chen, Lei
PHYTOMEDICINE, 2021, 82
[26] Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
Charu Gupta
Stefan Kaulfuss
Kerstin Görlich
Basem Othman
Anuhar Chaturvedi
Michael Heuser
Annals of Hematology, 2020, 99 : 1415 - 1417
[27] PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas
Koncar, Robert F.
Chu, Zhengtao
Romick-Rosendale, Lindsey E.
Wells, SusanneI.
Chan, Timothy A.
Qi, Xiaoyang
Bahassi, El Mustapha
ONCOTARGET, 2017, 8 (09) : 15827 - 15837
[28] Metabolic addiction in IDH1 mutant cancers
Chi, Andrew S.
Tateishi, Kensuke
Hiroaki, VVakimoto
Batchelor, Tracy T.
Lafrate, Anthony J.
Cahill, Daniel P.
CANCER RESEARCH, 2016, 76
[29] Mutant IDH1: An immunotherapeutic target in tumors
Schumacher, Theresa
Bunse, Lukas
Wick, Wolfgang
Platten, Michael
ONCOIMMUNOLOGY, 2014, 3 (12) : 1 - 2
[30] THE IDH1 MUTANT INHIBITOR AG-120 SHOWS STRONG INHIBITION OF 2-HG PRODUCTION IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO
Nicolay, Brandon
Narayanaswamy, Rohini
Aguado, Elia
Nagaraja, Raj
Murtie, Josh
Liu, Guowen
Ishii, Yuko
NEURO-ONCOLOGY, 2017, 19 : 86 - 86

← 1 2 3 4 5 →